- Investing Ideas
- French Pharmaceuticals & Biotech Top Stock Picks from Analysts
French Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
16
Companies which are more than 50% undervalued based on analyst price target.
16 companies
Inventiva
Market Cap: €750.2m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.28
7D
10.1%
1Y
23.4%
Valneva
Market Cap: €425.8m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.25
7D
2.1%
1Y
-6.0%
Transgene
Market Cap: €199.7m
A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
TNG
€0.73
7D
-0.5%
1Y
-7.5%
Cellectis
Market Cap: €184.8m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.85
7D
18.3%
1Y
107.1%
Innate Pharma
Market Cap: €149.6m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.60
7D
0.8%
1Y
5.0%
Sensorion
Market Cap: €130.5m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.25
7D
8.1%
1Y
-16.1%
Adocia
Market Cap: €81.5m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€4.28
7D
8.7%
1Y
11.7%
OSE Immunotherapeutics
Market Cap: €73.9m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.14
7D
3.0%
1Y
-38.6%
ABIONYX Pharma
Market Cap: €71.6m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€2.03
7D
-1.5%
1Y
68.0%
AB Science
Market Cap: €58.7m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.77
7D
-10.6%
1Y
-47.9%
MaaT Pharma
Market Cap: €49.7m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.64
7D
-2.4%
1Y
-50.2%
THX Pharma Société Anonyme
Market Cap: €45.7m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.31
7D
3.8%
1Y
231.0%
Nicox
Market Cap: €33.4m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
3.7%
1Y
68.3%
GenSight Biologics
Market Cap: €18.8m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.08
7D
-0.6%
1Y
-47.6%
Valbiotis
Market Cap: €18.7m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.83
7D
2.9%
1Y
0.7%
Advicenne
Market Cap: €18.1m
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.
ALDVI
€1.24
7D
21.5%
1Y
-9.3%